Mode
Text Size
Log in / Sign up

Intelligent pressure-control ureteral sheath improves outcomes in infection-related renal calculi surgery

Intelligent pressure-control ureteral sheath improves outcomes in infection-related renal calculi su…
Photo by Europeana / Unsplash
Key Takeaway
Consider FT-IPC UAS for potential efficiency gains in infection-related stone surgery, pending more complete data.

This randomized controlled trial enrolled 124 patients with infection-related renal calculi to compare a front-end flexible intelligent pressure-control ureteral access sheath (FT-IPC UAS) against a conventional sheath. The primary outcome was the 1-month stone-free rate, with secondary outcomes including intraoperative parameters, postoperative recovery, and complication rates over a 1-month follow-up period.

The main results indicated several advantages for the FT-IPC UAS group. The calculi-free rate was higher and the infection rate was markedly lower, though specific absolute numbers and effect sizes were not reported. Surgery time was significantly shorter (p < 0.001), peak perfusion pressure was lower (p < 0.001), and surgical field visibility was improved (p < 0.001). Postoperative inflammatory markers declined more in the intervention group (p < 0.001), and recovery was reported as faster. An analysis identified a procalcitonin (PCT) level > 0.5 ng/mL as an independent risk factor for postoperative infection, and a combined prediction model achieved an AUC of 0.8055.

Safety and tolerability data were not reported. Key limitations include the lack of reported absolute outcome numbers, effect sizes, and confidence intervals, which limits the precision of the findings. The funding source and potential conflicts of interest were also not reported. The restrained practice relevance is that the FT-IPC UAS may enhance surgical efficiency and accelerate recovery in this specific patient population, but the evidence remains preliminary due to incomplete data reporting.

Study Details

Study typeRct
Sample sizen = 124
EvidenceLevel 2
Follow-up1.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: This study attempts to evaluate the clinical performance and safety of a front-end flexible intelligent pressure-control ureteral access sheath (FT-IPC UAS) in retrograde intrarenal surgery (RIRS) for infection-related renal calculi. This research also aims to develop a predictive model for postoperative infection. METHODS: A total of 124 patients with renal calculi were prospectively enrolled and randomly assigned in a 1:1 ratio to the observation group (FT-IPC UAS) or the control group (conventional sheath). The primary endpoint was the 1-month stone-free rate (SFR). Intraoperative parameters, postoperative recovery outcomes, calculi-free rates, complication rates, and incidence of infection were compared. Logistic regression analysis was adopted to identify independent risk factors for postoperative infection. A multivariable prediction model was constructed and evaluated using receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and the Hosmer-Lemeshow goodness-of-fit test. RESULTS: The calculi-free rate was also higher in the observation group, while the infection rate was markedly lower. The observation group demonstrated significantly shorter surgery time, lower peak perfusion pressure, improved surgical field visibility, and declined postoperative inflammatory markers (all p < 0.001). Patients in the observation group experienced faster recovery. Multivariate regression analysis identified procalcitonin (PCT) > 0.5 ng/mL as an independent risk factor for postoperative infection. The combined prediction model yielded an AUC of 0.8055, indicating good predictive performance. CONCLUSIONS: The FT-IPC UAS enhances surgical efficiency, accelerates recovery, and reduces infection risk during RIRS. The predictive model incorporating PCT, sheath type, and surgery time offers reliable guidance for postoperative infection.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.